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Abstract
Background—Systolic blood pressure (SBP) often varies between clinic visits within
individuals, which can affect estimation of cardiovascular disease (CVD) risk.
Methods and Results—We analyzed data from participants with two clinic visits separated by
a median of 17 days in the Third National Health and Nutrition Examination Survey (n=808). Ten-
year CVD risk was calculated with SBP obtained at each visit using the Pooled Cohort Equations.
The mean age of participants was 46.1 years and 47.3% were male. The median SBP difference
between the two visits was −1 mmHg (1st – 99th percentiles: −23 to 32 mmHg). The median
estimated 10-year CVD risk was 2.5% and 2.4% at the first and second visit, respectively (1st –
99th percentiles −5.2% to +7.1%). Meaningful risk reclassification (i.e., across the guideline
recommended 7.5% threshold for statin initiation) occurred in 12 (11.3%) of 106 participants
whose estimated CVD risk was between 5% to 10%, but only in 2 (0.3%) of 702 participants who
had a 10-year estimated CVD risk of <5% or >10%.
Conclusions—SBP variability can affect CVD risk estimation, and can influence statin
eligibility for individuals with an estimated 10-year CVD risk between 5% and 10%.
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Introduction
The newly published American College of Cardiology (ACC)/ American Heart Association
(AHA) Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic
Cardiovascular Risk in Adults recommend estimating 10-year cardiovascular disease (CVD)
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risk using the Pooled Cohort Equations to guide initiation of statin therapy for primary
prevention.(1, 2) Systolic blood pressure is one of the measures used in the calculation of
estimated 10-year CVD risk.(1) Substantial change in systolic blood pressure between
sequential clinic visits has been noted in research studies and in clinical practice.(3–6) For
example, Rothwell et al. demonstrated that 15–35% of participants treated for hypertension
or who had a prior transient ischemic attack had changes in systolic blood pressure greater
than 50 mm Hg across multiple clinic visits.(3) Therefore, systolic blood pressure variability
has the potential to affect estimation of an individual's 10-year CVD risk, potentially leading
to uncertainty for the classification of patients into risk categories intended to guide
prevention efforts. However, scarce data are available on how likely this reclassification is
to occur.
With the release of the 2013 ACC / AHA guidelines that emphasize absolute CVD risk for
the initiation of statin therapy,(2) there is a need to characterize the impact of changes in
systolic blood pressure across clinic visits on the stability of CVD risk estimation. To
address this, we used data from the subset of participants in the Third National Health and
Nutrition Examination Survey (NHANES III) who completed two clinic visits over a period
of several weeks, to determine the effect of changes in systolic blood pressure across visits
on changes in estimated 10-year CVD risk.
Methods
NHANES III was a cross-sectional survey designed to select a representative sample of the
civilian non-institutionalized US population.(7) The protocol for NHANES III was approved
by the National Center for Health Statistics of the Centers for Disease Control and
Prevention Institutional Review Board, and all participants provided informed consent. Over
the survey period of 1988–1994, 18,825 adults ≥ 20 years of age completed an in-home
interview and a visit to a mobile clinic (Visit 1) for medical evaluation including three blood
pressure measurements. A subsample (n=2,174) attended a second visit at the mobile clinic
(Visit 2), at which time the medical evaluation, including three blood pressure
measurements, was repeated. The median duration between the two clinic visits was 17 days
(range, 1 to 48 days). Although more recent NHANES are available, we chose to analyze
NHANES III as it has data from a second study visit allowing for the calculation of
variability of blood pressure across two study visits. For the current analyses, we included
NHANES III participants who had two clinic visits with three blood pressure measurements
performed in the same arm at each visit (n=956). We excluded 32 participants missing data
on measures (e.g., total cholesterol) needed to calculate estimated 10-year CVD risk, and
116 participants with a history of coronary heart disease (CHD), diabetes, or stroke, as they
would be classified as having high CVD risk based on medical history alone.(2) After these
exclusions, 808 participants were included in this analysis.
Data Collection and Blood Pressure Measurement
Demographic and health-related information including age, sex, race/ethnicity, and smoking
status was collected using a standardized questionnaire during the in-home interview. The
use of anti-hypertensive medications was ascertained via self-report. Blood specimens were
collected during the medical evaluation to determine total cholesterol and high-density
lipoprotein (HDL) cholesterol levels. Blood pressure was measured three times during each
of the two clinic visits, with the average of the second and third measurements recorded as
the blood pressure for that visit. Blood pressure measurements were performed by a trained
clinician using the standard protocol of the American Heart Association at both clinic visits.
Each participant's arm was measured to determine the appropriate sized cuff. Participants
were asked to remain in a seated position for five minutes of quiet rest prior to their first
blood pressure measurement being taken. Quality control for the blood pressure
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measurements included quarterly recertification with retraining if necessary, annual
retraining of all physicians, and monitoring of equipment and equipment repair. Additional
details regarding blood pressure measurement and quality control procedures are provided in
the NHANES III manual of operations.(7)
Statistical Analysis
At each clinic visit, we calculated the participant's estimated 10 year CVD risk using the
Pooled Cohort Equations based on age, sex, race, systolic blood pressure, total cholesterol,
HDL cholesterol, smoking status, and use of antihypertensive medication.(1) In order to
isolate the effect of systolic blood pressure variability on estimated 10-year CVD risk, we
used the systolic blood pressure measured at each visit, while assuming other parameters
(e.g., cholesterol levels, smoking status) remain unchanged from the first visit. We then
computed the difference in 10-year CVD risk estimates calculated at the two visits, defined
as the risk estimate from Visit 2 minus the risk estimate from Visit 1. The summary
measures for number of days between clinic visits, systolic blood pressure, diastolic blood
pressure, and the estimated 10-year CVD risk at each visit were expressed as medians and
25th to 75th percentiles due to non-normal distributions of these variables. Agreement
between the two 10-year CVD risk estimates was assessed using a Bland-Altman plot,(8)
and the proportion of individuals with ≥1%, ≥2%, ≥3%, ≥4%, and ≥5% absolute change in
estimated 10-year CVD risk across two clinic visits was calculated. Next, we examined the
effect of change in blood pressure on change in estimated 10-year CVD risk across two
visits. First, we calculated the percentage of participants with systolic blood pressure < 130,
130 to < 150, and ≥ 150 mm Hg and diastolic blood pressure < 75, 75 to 84 and ≥ 85 mm Hg
at the first visit who experienced ≥3% absolute change in estimated 10-year CVD risk
between Visit 1 and Visit 2; ≥3% was chosen to represent a change large enough to have
potential clinical relevance. Using logistic regression models with systolic blood pressure <
130 mm Hg as the reference group, we analyzed whether systolic blood pressure between
130 to < 150 mm Hg and ≥ 150 mm Hg at time of Visit 1 were associated with a ≥3%
absolute change in estimated 10-year CVD risk at Visit 2 after multivariable adjustment. An
initial model adjusted for age, sex, race-ethnicity, and a second model further included
additional adjustment for diastolic blood pressure. Logistic regression models were also
constructed for diastolic blood pressure (<75 [reference], 75 to 84 and ≥ 85 mm Hg) with
two levels of adjustment for (Model 1) age, sex, race-ethnicity and (Model 2) age, sex, race-
ethnicity and systolic blood pressure.
Using 10-year CVD risk categories of <5%, 5% to <7.5%, 7.5% to <10%, and ≥10%,(2) we
calculated the proportion of participants who were reclassified from Visit 1 to Visit 2.
Specifically, we calculated the percentage of participants who stayed in the same risk-
category between Visits 1 and 2, were re-classified downwards (e.g., from ≥10% at Visit 1
to 7.5% to <10% at Visit 2), or were re-classified upwards (e.g., from 7.5% to <10% at Visit
1 to ≥10% at Visit 2). Examples of NHANES III participants whose risk categories changed
due to change in systolic blood pressure across the two clinic visits are provided to illustrate
the clinical implications of our findings. In a secondary analysis, we repeated the above
analysis using the Framingham risk equation for estimated 10-year CHD risk from the Adult
Treatment Panel III guidelines and the recommended risk categories of <10%, 10% to
<20%, and ≥20%.(9, 10)
All analyses were conducted without sampling weights as recommended for NHANES III
second examination data, and were performed using the statistical package SAS version 9.2
(SAS Institute, Cary, NC).
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Of the 808 participants included in the analyses, the mean (SD) age was 46.1 (17.2) years;
47.3% were men; 42.2% were non-Hispanic white; and 29.2% were current smokers (Table
1). The mean (SD) level for total cholesterol was 5.31 (1.08) mmol/L and for HDL
cholesterol was 1.31 (0.39) mmol/L. Overall, 14.5% of participants were taking
antihypertensive medications.
Blood Pressure and Estimated CVD Risk at Two Clinic Visits
At Visit 1, the median (25th to 75th percentiles) systolic blood pressure was 118 (108 to 131)
mm Hg (Table 2), and the median (25th to 75th percentiles) estimated 10-year CVD risk was
2.5% (0.5% to 10.0%). At Visit 2, the median (25th to 75th percentiles) systolic blood
pressure was 117 (107 to 129) mm Hg, and the median (25th to 75th percentiles) estimated
10-year CVD risk was 2.4% (0.5% to 10.0%). The median within-person differences in
systolic blood pressure between Visit 1 and Visit 2 was -1 mm Hg (1st to 99th percentiles,
−23 to 32 mmHg). For individual participants, changes in systolic blood pressure from Visit
1 to Visit 2 resulted in a wide distribution of changes in estimated 10-year CVD risk
(median = 0.0%; 1st to 99th percentiles –5.2% to +7.1%). Overall, 23% of participants had
an absolute difference in estimated 10-year CVD risk that was ≥1% across the 2 visits; 8%
of participants had an absolute difference that was ≥3%; and 4% of participants had an
absolute difference that was ≥5% (Figure 1). On average, the difference in estimated 10-year
CVD risk between the two visits was larger for individuals with higher estimated risk
(Figure 2).
Overall, 2.9% of participants with systolic blood pressure < 130 mm Hg at Visit 1 had a
≥3% absolute change in estimated 10-year CVD risk between Visits 1 and 2, compared to
13.6% and 36.0% of participants with systolic blood pressure 130–149 and ≥150 mm Hg,
respectively, at Visit 1 (Table 3, top panel). After adjustment for age, gender, race-ethnicity,
and diastolic blood pressure and compared to participants with systolic blood pressure < 130
mm Hg at Visit 1, the odds ratio for having a ≥3% absolute change in estimated 10-year
CVD risk between Visits 1 and 2 associated with systolic blood pressure of 130–149 mm Hg
and ≥150 mm Hg were 1.86 (95% CI 0.84–4.12) and 5.60 (95% CI 2.23–14.1), respectively.
In contrast, no association was present between diastolic blood pressure categories and
having a ≥3% between-visit absolute change in estimated 10-year CVD risk (Table 3,
bottom panel).
Reclassification Due to Changes in Blood Pressure
For participants with an estimated 10-year CVD risk of < 5% at Visit 1, 1.2% were
reclassified upwards at Visit 2, including 1 participant who was reclassified into the 7.5% to
<10% category (Table 4). In contrast, 12.1% of participants who had an estimated 10-year
CVD risk in the 5% to <7.5% category at Visit 1 were reclassified downwards to the < 5%
category, while 10.3% were re-classified upwards to the 7.5% to <10% category. Similarly,
12.5% of participants with an estimated 10-year CVD risk in the 7.5% to <10% category at
Visit 1 were reclassified downwards to the 5% to <7.5% category and 10 (20.8%) were
reclassified upwards into the ≥10% category at Visit 2. Finally, 4.5% of participants with
estimated 10-year CVD risk of ≥10% at Visit 1 were reclassified downwards at Visit 2,
including 1 participant who was reclassified into the 5% to <7.5% category. Using the
Framingham risk equation recommended in the ATP III guidelines and categories of <10%,
10% to 20%, and >20% of estimated 10-year CHD risk, reclassification from Visit 1 to Visit
2 due to change in systolic blood pressure primarily occurred in those in the highest
estimated risk category (Table 5).
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We provide examples of two NHANES participants who were reclassified into different 10-
year CVD risk categories due to change in systolic blood pressure across two clinic visits in
Table 6.
Discussion
In the current study, we demonstrated that change in systolic blood pressure between clinic
visits could affect estimation of 10-year CVD risk using the recently published Pooled
Cohort Equations. This effect was especially prominent in individuals with an estimated 10-
year CVD risk between 5% and 10%. However, reclassification in estimated 10-year CVD
risk categories occurred in a very small percentage of individuals at low (i.e., <5%) or high
(i.e., ≥10%) estimated risk. The reclassification of risk associated with changes in systolic
blood pressure between clinic visits is not unique to the Pooled Cohort Equations, as similar
reclassification also occurred using the Framingham 10-year CHD risk equation.
Substantial blood pressure variability has been reported in previous studies. We have
described a mean standard deviation of 7.7 mm Hg for systolic blood pressure across three
visits (two clinic visits and one home visit) in a subsample of NHANES III participants, as
well as a mean standard deviation of 10.9 mm Hg for systolic blood pressure measured
across eleven visits in the Women's Health Initiative.(4, 11) Systolic blood pressure
variability of a similar magnitude or greater has also been described in patients treated for
hypertension or prior transient ischemic attack,(3) and in patients with hypertension
followed in primary care clinics.(5) Our current analysis suggests that these levels of blood
pressure variability (3–5, 11) can affect estimation of cardiovascular risk using the Pooled
Cohort Equations recommended by current guidelines.(1) Especially for individuals whose
estimated 10-year CVD risk is near the 7.5% cut-point recommended for treatment decisions
in the newly published ACC/AHA Guideline on the Treatment of Blood Cholesterol,(2)
systolic blood pressure variability may result in uncertainty for clinical decisions such as
statin initiation.
Although the current analysis focused on 10-year CVD risk estimated using the Pooled
Cohort Equation, the issue of blood pressure variability is likely relevant to other methods of
CVD and CHD risk prediction. As we have demonstrated, change in systolic blood pressure
across clinic visits also affected the Framingham equation estimated 10-year CHD risk.
Systolic blood pressure is also part of other commonly used risk prediction tools such as the
Reynolds, the QRISK, and the SCORE risk scores,(12–14) and the stability of risk
classification with these other methods may be affected by blood pressure variability. The
increased emphasis on absolute risk in current national and international cardiovascular
disease prevention guidelines (2, 15) suggest that that the stability of risk estimation is an
issue that warrants further investigation.(16) Given the known challenges of applying risk
prediction methods derived from populations to individual clinical encounters,(17) more
study is also needed to determine whether and how to discuss the stability of risk
classification during shared decision making processes.(18)
Our results also provide guidance for the appropriate use of Pooled Cohort Equations to
estimate 10-year CVD risk in real-world settings. It is reassuring that we found change in
systolic blood pressure across clinic visits meaningfully impacted estimation of 10-year
CVD risk in only a small percentage of participants with 10-year CVD risk estimated to be
<5% or ≥10%. These results suggest that systolic blood pressure measured at a single visit is
sufficient when the estimated CVD risk is in these ranges. However, for individuals whose
initial estimated risk is between 5% to 10%, we found that reclassification may occur for a
substantial percentage of individuals due to change in systolic blood pressure. For these
individuals, there is potential for over- or under-treatment with statin therapy if the clinical
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decision-making is guided solely by risk estimation at the initial visit. Further research is
needed to clarify the extent to which repeat blood pressure measurements are needed to
reliably estimate cardiovascular risk and to avoid under or over-treatment with statins.
Our study has several strengths. First, the NHANES data we used includes a broad cross-
section of the US population, making our results highly generalizable. Second, blood
pressure measurements in NHANES were performed by trained physicians following a
standardized protocol, suggesting that the reclassification observed was due to within-person
variability in blood pressure rather than measurement error. In addition, the two blood
pressure measurements were taken only several weeks apart, making it less likely that our
results are due to natural progression of hypertension or to changes in medication regimens.
Taken together, our findings add to the emerging literature on the inherent challenges for
applying population-derived risk prediction tools such as the Pooled Cohort Equations to
individual clinical encounters.(17, 19)
There are also several limitations to our study. Our sample size was limited by the number
of NHANES III participants with two clinic visits, which represents only a subset of
NHANES III cohort. However, the distribution of estimated cardiovascular risk in our
sample is similar to what has been previously reported for the entire NHANES III cohort,
(20) suggesting that our findings are not due to sampling or selection bias. As we calculated
systolic blood pressure using the average of the second and third measurements at each visit,
caution is also needed to generalize our results to clinical settings where blood pressure
reading is often obtained through a single measurement without necessarily following a
standardized protocol. However, systolic blood pressure measured in such settings will
likely have higher variability across visits.(21) Finally, our analysis focused on risk
estimation rather than hard clinical endpoints. However, our previous analysis of this study
population also demonstrated that visit-to-visit variability of systolic blood pressure was
associated with all-cause mortality, and was correlated with factors such as higher mean
systolic blood pressure and the use of angiotensin converting enzyme-inhibitors.(4) Our
results will need to be validated in future studies, and the clinical impact of uncertainty in
risk estimation caused by systolic blood pressure variability will require further clarification.
In conclusion, we found that change in systolic blood pressure across clinic visits has a
clinically meaningful effect on estimation of 10-year CVD risk using the Pooled Cohort
Equations, especially for individuals whose estimated risk is near the 7.5% cut-point
recommended for consideration of statin therapy. These results may be useful to guide
interpretation of estimated 10-year CVD risk during individual clinical encounters where
statin initiation is considered, and suggest that there is a need to better understand the effect
of blood pressure variability on the stability of risk classification for risk prediction
methods.
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Figure 1. Percentage of participants with an absolute change in estimated 10-year cardiovascular
disease (CVD) risk ≥ 1% to ≥ 5% resulting from change in systolic blood pressure across two
clinic visits.
Absolute change in estimated 10-year CVD risk is calculated as the absolute difference
between Pooled Cohort Equations derived risk estimates determined at clinic visit 1 and
clinic visit 2, using systolic blood pressure measured at each visit while holding all other
variables constant.
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Bland-Altman plot for comparison of estimated 10-year cardiovascular disease (CVD) risk
calculated using the Pooled Cohort Equations at two clinic visits.
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Table 1
Characteristics of NHANES III participants who had blood pressure measurements at two clinic visits.
Characteristic N=808
Age, years 46.1 (17.2)
Male sex 47.3%
Race-ethnicity
 Non-Hispanic white 42.2%
 Non-Hispanic black 27.9%
 Mexican American 25.7%
 Other 4.2%
Current smoking 29.2%
Total cholesterol, mmol/L 5.31 (1.08)
HDL-cholesterol, mmol/L 1.31 (0.39)
On antihypertensive treatment 14.5%
HDL, high-density lipoprotein; numbers in table are mean (standard deviation) or percentage.
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Table 2
Systolic and diastolic blood pressure and Pooled Cohort Equations estimated 10-year cardiovascular disease
risk at each NHANES III visit.
Percentile
1st 25th 50th 75th 99th
Clinic Visit 1 BP, mmHg
 Systolic 91 108 118 131 180
 Diastolic 47 65 73 80 100
Clinic Visit 2 BP, mmHg
 Systolic 90 107 117 129 174
 Diastolic 46 65 72 79 97
Difference in BP, mmHg (clinic visit 2 - clinic visit 1)
 SBP −23 −7 −1 4 32
 DBP −17 −5 0 4 21
Estimated 10-year CVD risk*, %
 Clinic Visit 1 SBP <0.1% 0.5% 2.5% 10.0% 49.9%
 Clinic Visit 2 SBP <0.1% 0.5% 2.4% 10.0% 45.8%
Differences in estimated 10-year CVD risk, % (clinic visit 1 - clinic visit 2) −5.2% −0.1% 0.0% 0.3% 7.1%
BP: blood pressure; SBP, systolic blood pressure; DBP, diastolic blood pressure; CVD: cardiovascular disease.
*
Estimated 10-year CVD risk are calculated from the Pooled Cohort Equations recommended by the American College of Cardiology Foundation /
American Heart Association 2013 Guideline on the Assessment of Cardiovascular Risk.
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Table 3
Percent of participants whose estimated 10-year cardiovascular disease (CVD) risk was ≥3% different due to
systolic blood pressure variability between two clinic visits and odds ratios for ≥3% difference by categories
of systolic blood pressure (top panel) and diastolic blood pressure (bottom panel).
Systolic blood pressure from Visit 1, mm Hg
< 130 (n=579) 130 – 149 (n=154) >≥ 150 (n=75)
% with ≥3% change in 10-year CVD risk 2.9% 13.6% 36.0%
Odds ratio (95% Cl) for reclassification
Model 1 1 (ref) 1.76(0.80 – 3.84) 4.72(2.06 – 10.8)
Model 2† 1 (ref) 1.86(0.84 – 4.12) 5.60(2.23 – 14.1)
Diastolic blood pressure from Visit 1, mm Hg
< 75 (n=457) 75 – 84 (n=222) ≥ 85 (n=129)
% with ≥3% change in 10-year CVD risk 7.4% 9.9% 7.0%
Odds ratio (95% Cl) for reclassification
Model 1 1 (ref) 1.35(0.68 – 2.69) 1.41(0.55 – 3.66)
Model 2†† 1 (ref) 1.00(0.48 – 2.06) 0.60(0.21 – 1.78)
Model 1 includes adjustment for age, gender, and race-ethnicity
†
Model 2 includes adjustment for age, gender, race-ethnicity, and diastolic blood pressure
††
Model 2 includes adjustment for age, gender, race-ethnicity, and systolic blood pressure
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Table 4
Reclassification of estimated 10-year cardiovascular disease (CVD) risk of NHANES III participants due to
change in systolic blood pressure across two clinic visits.
Estimated 10-year CVD risk at Visit 1
Estimated 10-year CVD risk at Visit 2 <5% 5 to <7.5% 7.5% to <10% ≥10%
<5% 494 (98.8%) 7 (12.1%) 0 (0%) 0 (0%)
5 to <7.5% 5 (1.0%) 45 (77.6%) 6 (12.5%) 1 (0.5%)
7.5% to <10% 1 (0.2%) 6 (10.3%) 32 (66.7%) 8 (4.0%)
≥ 10% 0 (0%) 0 (0%) 10 (20.8%) 193 (95.5%)
Total 500 (61.9%) 58 (7.2%) 48 (5.9%) 202 (25.0%)
CVD, cardiovascular disease; numbers in table are n (%).
*Percentages are calculated per column using the total number of participants in each Clinic Visit 1 estimated 10-year CVD risk category as
denominator; may not add up to 100% due to rounding
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Table 5
Reclassification of Framingham equation estimated 10-year coronary heart disease (CHD) risk in NHANES
III participants due to change in systolic blood pressure across two clinic visits.
Estimated 10-year CHD risk at Visit 1
Estimated 10-year CHD risk at Visit 2 <10% 10–20% >20%
<10% 633 (98.9%) 14 (10.9%) 0 (0%)
10–20% 7 (1.1%) 110 (85.9%) 10 (25.0%)
>20% 0 (0%) 4 (3.1%) 30 (75.0%)
Total 640 (100%) 128 (100%) 40 (100%)
CHD, coronary heart disease; numbers in table are n (%).
*Percentages are calculated per column using the total number of participants in each Clinic Visit 1 estimated 10-year CHD risk category as
denominator; may not add up to 100% due to rounding.
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Table 6
Examples of NHANES III participants whose Pooled Cohort Equations estimated 10-year CVD risk were
reclassified due to change in systolic blood pressure across two clinic visits.
Participant A
A 41 year old African-American woman with total cholesterol of 4.27 mmol/L, HDL of 1.03 mmol/L, and SBP of 145 mm Hg at clinic visit 1.
She is a smoker and is not on medication treatment for hypertension. Her Pooled Cohort Equations estimated 10-year CVD risk is 4.2%. At
clinic visit 2, her SBP is 166 mm Hg, which changes her estimated 10-year CVD risk to 8.4%.
Participant B
A 46 year old nonHispanic white man with total cholesterol of 6.52 mmol/L, HDL of 0.78 mmol/L, and SBP of 149 mm Hg at clinic visit 1. He
does not smoke and does not take any antihypertensive medications. His Pooled Cohort Equations estimated 10-year CVD risk is 7.9%. At
clinic visit 2, his SBP is 140 mm Hg, which changes his estimated 10-year CVD risk to 7.1%.
CVD: cardiovascular disease; HDL, high-density lipoprotein; SBP, systolic blood pressure.
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